Guillermo Amescua

About Guillermo Amescua

“My work has focused on advancing the management of infectious keratitis, strengthening ophthalmic education, and fostering international collaboration to improve patient outcomes globally.

“As a cornea specialist and Medical Director of the Ocular Microbiology Laboratory at Bascom Palmer, I have led initiatives to optimize rapid diagnostics and antimicrobial stewardship for severe corneal infections. These efforts aim to reduce time-to-effective therapy and improve visual outcomes in complex cases. A major priority has been the development and evaluation of innovative treatments, including photodynamic antimicrobial strategies, through multicenter clinical trials in collaboration with Stanford University, Aravind Eye Hospital, and the Proctor Foundation. These partnerships are critical to generating high-quality evidence that informs global standards of care for fungal and Acanthamoeba keratitis.

“Teaching remains central to my mission. I actively train residents and fellows in advanced surgical techniques – such as complex cataract surgery, ocular surface reconstruction, mucous membrane grafting, amniotic membrane transplantation, and keratoplasty – while guiding them through evidence-based decision-making for infectious keratitis. Beyond the operating room, I mentor trainees in research methodology, preparing the next generation of ophthalmologists to lead in both clinical and academic arenas.

“As Co-Director of the Bascom Palmer Interamerican Course, I have expanded bilingual educational offerings to strengthen ophthalmic care across Latin America. This course serves as a platform for knowledge exchange, equipping regional surgeons with practical strategies for managing complex ophthalmic conditions, and more recently giving an important emphasis to surgical simulation with wet and dry labs during the course. Additionally, I chaired the Copenhagen ESCRS 2025 symposium “Infectious Keratitis: Defeating the Enemy,” which brought together global experts to share best practices in fungal and Acanthamoeba keratitis management.

The impact of these efforts is multifaceted:

• Clinical care. Streamlined microbiology–clinic workflows and standardized treatment protocols for infectious keratitis.

• Education. Enhanced surgical training and international courses that disseminate cutting-edge practices to diverse audiences.

• Research. Collaborative trials that aim to establish new therapeutic paradigms for sight-threatening infections.

“Looking ahead, I am committed to scaling these collaborations, integrating AI-driven diagnostics, and expanding modular curricula to ensure that advances in infectious keratitis translate into measurable improvements in vision preservation worldwide.”